| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.26 | 4e-10 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-05 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.22 | 5e-05 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.0001 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0004 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.23 | 0.0005 |